# Kamada Ltd > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Kamada Ltd). ## Overview Kamada Ltd. is a biopharmaceutical company focused on plasma-derived therapies for rare and serious conditions. Its business combines proprietary plasma products, plasma collection operations in the United States, and distribution of third-party pharmaceutical products in Israel and the MENA region through its subsidiaries and commercial network. ## Products & services • Plasma-derived specialty therapeutics • Normal source plasma collection and supply • FDA-approved immunoglobulin and immune globulin products • Equine-based anti-snake venom products • Third-party pharmaceutical distribution in Israel and MENA - **Specialty plasma-derived therapeutics** (55%) — Commercial plasma-derived medicines used in rare and serious conditions. - **Normal source plasma supply** (20%) — Plasma collected in the U.S. and sold to other plasma-derived manufacturers. - **Third-party pharmaceutical distribution** (15%) — Imported and in-licensed drugs distributed mainly in Israel and MENA. - **Hyper-immune and anti-snake venom products** (10%) — Specialty immune plasma and equine-based anti-venom products sold in select markets. - Plasma-derived specialty therapeutics - Normal source plasma collection and supply - FDA-approved immunoglobulin and immune globulin products - Equine-based anti-snake venom products - Third-party pharmaceutical distribution in Israel and MENA ## Customers Kamada sells to healthcare providers, hospitals, distributors, and other pharmaceutical manufacturers that need plasma-derived inputs or finished specialty medicines. It also distributes third-party pharmaceuticals to patients and healthcare systems in Israel and the broader MENA region through local commercialization partnerships. For its plasma business, the direct customers are other biopharmaceutical companies that use source plasma as a raw material for downstream therapies. - **Biopharmaceutical manufacturers** (primary) — Buy source plasma for use in downstream plasma-derived therapies. - **Hospitals and specialty clinicians** (primary) — Use branded plasma-derived medicines for rare and serious conditions. - **Israel and MENA healthcare markets** (secondary) — Buy distributed third-party pharmaceuticals and biosimilars through local channels. - **Public health and emergency buyers** (secondary) — Use hyper-immune and anti-snake venom products in niche treatment settings. - Hospitals and clinicians using rare-disease plasma therapies - Biopharmaceutical manufacturers buying source plasma - Israel and MENA distributors and healthcare systems - Patients needing immune globulin and specialty biologics - Public-health and emergency channels using anti-venom products ## Geography Kamada is globally oriented, with commercial and manufacturing activity tied to Israel, the United States, and selected markets in the Middle East and North Africa. Its plasma collection footprint is centered in Texas, where it operates FDA-approved centers in Beaumont, Houston, and San Antonio. The business also relies on Israel for corporate, development, and distribution activities, while MENA remains important for in-licensed products and regional sales. - Texas plasma centers support U.S.-based collection and supply - Israel is a core base for distribution and commercial operations - MENA is a key market for third-party and in-licensed products - U.S. operations support vertical integration into plasma supply - Regional exposure affects regulation, logistics, and market access ## Strategy Kamada’s strategy is built around four pillars: growing its proprietary plasma-therapy portfolio, expanding distribution in Israel and MENA, scaling plasma collection, and adding products or businesses through in-licensing, collaboration, or M&A. The company is using its plasma centers and manufacturing capabilities to strengthen vertical integration, secure more control over supply, and support long-term commercialization of rare-disease therapies. - **Scale proprietary plasma therapies** (medium-term) — These products are the core branded franchise and anchor the company's rare-disease presence. - **Expand plasma collection capacity** (short-term) — In-house source plasma improves supply security and creates an additional revenue stream. - **Grow distribution in Israel and MENA** (medium-term) — Regional distribution diversifies revenue beyond proprietary plasma products. - **Pursue business development and M&A** (long-term) — Additions to the portfolio can deepen the pipeline and broaden the commercial base. - Grow proprietary plasma therapies through commercialization and lifecycle management - Expand plasma collection to support internal and third-party supply - Broaden Israel and MENA distribution through in-licensing and biosimilars - Pursue M&A and business development to expand the marketed portfolio - Use vertical integration to improve supply access and operating leverage ## Risks Kamada depends on regulated plasma collection, manufacturing quality, and continued access to donor plasma, so operational disruptions or regulatory issues could affect supply and sales. The company also faces concentration risk in niche rare-disease products, regional exposure in Israel and MENA, and the typical biologics risks of pricing pressure, competition, and product obsolescence. Because it operates across multiple jurisdictions and uses partnerships for distribution and sourcing, execution risk and compliance risk are structurally important. - **Plasma supply disruption** [high] — The business needs steady donor collections to support both external sales and internal product needs. - **Regulatory and quality compliance** [high] — Blood product collection and biologics manufacturing require strict FDA and health-authority oversight. - **Portfolio concentration** [medium] — A limited number of branded plasma therapies can drive a large share of commercial performance. - **Geopolitical and market-access risk** [medium] — Sales and distribution in Israel and MENA can be affected by regional instability and import rules. - Plasma collection depends on donor supply and center execution - FDA and health-authority compliance is critical for collection and products - Rare-disease product concentration increases dependence on a small portfolio - Israel and MENA exposure creates geopolitical and regulatory risk - Partnerships and in-licensing add execution and counterparty risk ## Accounting Kamada’s reporting is affected by revenue timing across proprietary products, plasma supply agreements, and distribution arrangements, which can vary by delivery point and commercial milestones. Lease accounting is relevant because the company operates U.S. collection centers and other facilities, while fair value and impairment judgments can matter for intangible assets, product rights, and any acquired businesses. As a biopharma company, it also relies on estimates for returns, reserves, and forward-looking measures such as adjusted EBITDA. - **Revenue recognition** — Can shift reported quarterly revenue timing - **Lease accounting** — Affects balance sheet leverage and operating expense presentation - **Intangible asset impairment** — Can materially affect earnings if product value assumptions change - **Non-IFRS measures** — Can influence how investors assess operating performance - Revenue recognition varies by product sales, supply contracts, and distribution arrangements - Plasma supply agreements may create timing differences around delivery and acceptance - Lease accounting matters for plasma centers and operational facilities - Intangible assets and acquired products may require impairment testing - Adjusted EBITDA and other non-IFRS measures depend on management estimates --- *Last updated: 2026-09-28T12:04:12.144468+00:00*